Caladrius Biosciences Stock News

BASKING RIDGE, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the d

Caladrius Biosciences is focused on treating coronary microvascular dysfunction. The condition is most common among women, especially after menopause.

The stock price of Caladrius Biosciences Inc (NASDAQ: CLBS) is trading at more than 130% pre-market today. This is why it happened.

Initiation of the Phase 2b FREEDOM trial represents the next step in development of CLBS16 as a potential breakthrough treatment for the millions of sufferers of CMD in the U.S., most of whom are wome

BASKING RIDGE, N.J., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the de

BASKING RIDGE, N.J., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the de

The Company retains Robert Honigberg, M.D., as interim Chief Medical Officer The Company retains Robert Honigberg, M.D., as interim Chief Medical Officer

BASKING RIDGE, N.J., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the de

Caladrius Biosciences' (CLBS) CEO David Mazzo on Q3 2020 Results - Earnings Call Transcript

BASKING RIDGE, N.J. , Nov. 04, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the d

BASKING RIDGE, N.J., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the de

BASKING RIDGE, N.J., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the de

Caladrius Biosciences, Inc. (NASDAQ:CLBS) Q2 2020 Earnings Conference Call August 13, 2020 4:30 PM ET Company Participants John Menditto – Vice President, Investor Relations and Corporate Communicat

Clinical programs advanced and expanded with strengthened cash positionConference call begins today at 4:30 p.m. Eastern timeBASKING RIDGE, N.J., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Caladrius Bioscienc

Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus...